Hepatitis B Vaccine Less Effective in Patients With Rheumatoid Arthritis

Rheumatoid arthritis is a chronic systemic disease that affects the joints, connective tissues, muscle, tendons and fibrous tissue among women.

People with rheumatoid arthritis (RA) are less likely to be protected by hepatitis B vaccination than the general population, claims new research.

Within the trial, only 11% of those with the condition responded to the vaccine, compared with 83% of those without RA.

Rates of Hepatitis B Vaccination Among Injecting Drug Users Improves With Small Cash Incentives
A dramatic increase in likelihood of people who inject drugs completing a course of hepatitis B virus vaccination was seen with small cash incentives, totaling as little as £30.

"The majority of RA patients tested as part of our study were not protected by hepatitis B vaccination," said study investigator Misha Tilanus from Radboud University’s Medical Center in Netherlands.

"People with RA have an increased risk of morbidity and mortality from infections, and to discover that immunization might not confer protection is a real concern. It’s crucial that patients and healthcare practitioners are aware of this lack of efficacy and do all they can to minimize risk," Tilanus said.

The results were presented at the European League Against Rheumatism Annual Congress.

Antiviral Drug Telbivudine Prevents Transmission of Hepatitis B Virus During Pregnancy
Telbivudine eliminated vertical transmission of HBV from pregnant women to their infants, and it is also safe and well tolerated by mother and child.

RA is a chronic systemic disease that affects the joints, connective tissues, muscle, tendons and fibrous tissue.

The prevalence of RA globally varies between 0.3-1% and is more common in women and in developed countries.

Doctors to Study High Prevalence of Hepatitis B and C in Himachal Pradesh
High Prevalence of Hepatitis B and C viruses in the Indian state may be due to unscreened blood transfusions, and the use of unsterilized needles and syringes.

RA -- and many of its treatments -- can suppress the immune system, leaving patients at risk of a potentially fatal infection.

For the study, vaccination with HBVAXPRO-10 was performed according to the standard regimen (0, 1 and 6 months), with markers of response to the vaccine (hepatitis B antigens, anti-HBsAG) determined after 28 weeks.

Entecavir, An Effective Antiviral Drug, may Help Treat Hepatitis B Virus Infection
Hepatitis B drug, entecavir, could be mass produced for only $36 per person per year. Combining mass vaccination with mass treatment would lower death rates.

RA patients had a higher risk for non-response than controls.

Source-IANS